Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids: Enrichment for Mitotic Inhibitors with Hydrophobic Properties

Chemical Biology and Drug Design

Volumn 78, Issue 4, 2011, Pages 547-557

  Fayad, Walid ^a   Rickardson, Linda ^b   Haglund, Caroline ^b   Olofsson, Maria Hägg ^a   D'Arcy, Padraig ^a   Larsson, Rolf ^b   Linder, Stig ^a   Fryknäs, Mårten ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticancer drugs; Apoptosis; Microtubuli inhibitors; Solid tumours; XLogP

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PODOPHYLLOTOXIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; COLON CARCINOMA; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROPHOBICITY; HYPOXIA; MICROTUBULE; PRIORITY JOURNAL; TUMOR SPHEROID;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; COLONIC NEOPLASMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MITOSIS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 80052640508     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01170.x     Document Type: Article

References (45)

1. Hadaschik B.A., Sowery R.D., Gleave M.E. (2007) Novel targets and approaches in advanced prostate cancer. Curr Opin Urol;17:182-187.
2. Curtin J.F., King G.D., Candolfi M., Greeno R.B., Kroeger K.M., Lowenstein P.R., Castro M.G. (2005) Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem;5:1151-1170.
3. Melisi D., Troiani T., Damiano V., Tortora G., Ciardiello F. (2004) Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr Relat Cancer;11:51-68.
4. Smalley K.S., Lioni M., Herlyn M. (2006) Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim;42:242-247.
5. Sutherland R.M. (1988) Cell and environment interactions in tumor microregions: the multicell spheroid model. Science;240:177-184.
6. Olive P.L., Durand R.E. (1994) Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev;13:121-138.
7. Kobayashi H., Man S., Graham C.H., Kapitain S.J., Teicher B.A., Kerbel R.S. (1993) Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A;90:3294-3298.
8. Sutherland R.M., Eddy H.A., Bareham B., Reich K., Vanantwerp D. (1979) Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys;5:1225-1230.
9. Tunggal J.K., Cowan D.S., Shaikh H., Tannock I.F. (1999) Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res;5:1583-1586.
10. Tannock I.F., Lee C.M., Tunggal J.K., Cowan D.S., Egorin M.J. (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res;8:878-884.
11. Carlsson J., Gedda L. (2006) Penetration of tumor therapy interesting substances in non-vascularized metastases: review of studies in multicellular spheroids. Curr Cancer Ther Rev;2:293-304.
12. Mueller-Klieser W. (1987) Multicellular spheroids. A review on cellular aggregates in cancer research. J Cancer Res Clin Oncol;113:101-122.
13. Zietarska M., Maugard C.M., Filali-Mouhim A., Alam-Fahmy M., Tonin P.N., Provencher D.M., Mes-Masson A.M. (2007) Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog;46:872-885.
14. Sutherland R.M., Durand R.E. (1976) Radiation response of multicell spheroids - an in vitro tumour model. Curr Top Radiat Res Q;11:87-139.
15. Frankel A., Buckman R., Kerbel R.S. (1997) Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res;57:2388-2393.
16. Herrmann R., Fayad W., Schwarz S., Berndtsson M., Linder S. (2008) Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. J Biomol Screen;13:1-8.
17. Hägg M., Biven K., Ueno T., Rydlander L., Björklund P., Wiman K.G., Shoshan M.C., Linder S. (2002) A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs;20:253-259.
18. Friedrich J., Eder W., Castaneda J., Doss M., Huber E., Ebner R., Kunz-Schughart L.A. (2007) A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J Biomol Screen;12:925-937.
19. Lindhagen E., Nygren P., Larsson R. (2008) The fluorometric microculture cytotoxicity assay. Nat Protoc;3:1364-1369.
20. Fayad W., Brnjic S., Berglind D., Blixt S., Shoshan M.C., Berndtsson M., Olofsson M.H., Linder S. (2009) Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. Int J Cancer;125:2450-2455.
21. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J. et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science;313:1929-1935.
22. Kelm J.M., Timmins N.E., Brown C.J., Fussenegger M., Nielsen L.K. (2003) Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng;83:173-180.
23. Kaufmann S.H., Earnshaw W.C. (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res;256:42-49.
24. Erdal H., Berndtsson M., Castro J., Brunk U., Shoshan M.C., Linder S. (2005) Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A;102:192-197.
25. Fayad W., Fryknäs M., Brnjic S., Berndtsson M., Olofsson M.H., Larsson R., Linder S. (2009) Identification of a novel topoisomerase inhibitor effective in multicellular spheroids and in cells overexpressing drug efflux transporters. PLoS One;4:e7238.
26. Wang R., Fu Y., Lai L. (1997) A new atom-additive method for calculating partition coefficients. J Chem Inf Comput Sci;37:615-621.
27. Ben-Ze'ev A., Farmer S.R., Penman S. (1979) Mechanisms of regulating tubulin synthesis in cultured mammalian cells. Cell;17:319-325.
28. Banerjee M., Poddar A., Mitra G., Surolia A., Owa T., Bhattacharyya B. (2005) Sulfonamide drugs binding to the colchicine site of tubulin: thermodynamic analysis of the drug-tubulin interactions by isothermal titration calorimetry. J Med Chem;48:547-555.
29. Downing K.H., Nogales E. (1998) Tubulin structure: insights into microtubule properties and functions. Curr Opin Struct Biol;8:785-791.
30. Hamel E. (1996) Antimitotic natural products and their interactions with tubulin. Med Res Rev;16:207-231.
31. Ross-Macdonald P., de Silva H., Guo Q., Xiao H., Hung C.Y., Penhallow B., Markwalder J., et al. (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther;7:3490-3498.
32. Leoni L.M., Hamel E., Genini D., Shih H., Carrera C.J., Cottam H.B., Carson D.A. (2000) Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst;92:217-224.
33. Gundersen G.G., Cook T.A. (1999) Microtubules and signal transduction. Curr Opin Cell Biol;11:81-94.
34. Lloyd D.G., Golfis G., Knox A.J., Fayne D., Meegan M.J., Oprea T.I. (2006) Oncology exploration: charting cancer medicinal chemistry space. Drug Discov Today;11:149-159.
35. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev;46:3-26.
36. Congreve M., Carr R., Murray C., Jhoti H. (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today;8:876-877.
37. Grantab R., Sivananthan S., Tannock I.F. (2006) The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res;66:1033-1039.
38. Radhakrishnan S.K., Bhat U.G., Hughes D.E., Wang I.C., Costa R.H., Gartel A.L. (2006) Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res;66:9731-9735.
39. van Zuylen L., Verweij J., Sparreboom A. (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs;19:125-141.
40. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R., Jr, et al. (1990) Hypersensitivity reactions from taxol. J Clin Oncol;8:1263-1268.
41. Engels F.K., Mathot R.A., Verweij J. (2007) Alternative drug formulations of docetaxel: a review. Anticancer Drugs;18:95-103.
42. Hennenfent K.L., Govindan R. (2006) Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol;17:735-749.
43. Arteel G.E., Thurman R.G., Raleigh J.A. (1998) Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem;253:743-750.
44. Morgan U.M., Reynoldson J.A., Thompson R.C. (1993) Activities of several benzimidazoles and tubulin inhibitors against Giardia spp. in vitro. Antimicrob Agents Chemother;37:328-331.
45. Koeller K.M., Haggarty S.J., Perkins B.D., Leykin I., Wong J.C., Kao M.C., Schreiber S.L. (2003) Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem Biol;10:397-410.